myRocky Review
Best for: US patients in the 42 supported states who specifically want brand-name FDA-approved GLP-1 receptor agonists without insurance involvement AND are also managing additional conditions covered by myRocky's multi-product platform (sexual health, hair loss, mental health) so the $99/mo program fee amortizes across multiple medications. NOT recommended for patients sensitive to total monthly cost — compounded providers ($99-$199/mo) and direct manufacturer programs (NovoCare, LillyDirect) offer better economics.
myRocky (myrocky.com) is a Canadian-incorporated multi-product telehealth platform — Rocky Health Inc., Mississauga, Ontario — that markets brand-name GLP-1 receptor agonists (Ozempic, Mounjaro, Wegovy) to US patients in 42 states with Phase-2 expansion pending in 8 more (DE, HI, MS, NH, NM, NC, RI, VT). The platform is multi-product, also offering sexual health, hair loss, and mental health services. US-state prescriber and pharmacy operationalization is opaque on public-facing pages; the listed pharmacy (Rocky Pharmacy #308582, Mississauga ON) is a Canadian community pharmacy. The fee structure stacks: $99 initial consultation + $99/mo program fee + the cost of the medication itself (Ozempic listed at $1,409/mo). LegitScript #44796030.
Medium confidence · Last verified 2026-05-15 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
myRocky is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
myRocky prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Brand 0.25/0.5/1/2 mg | brand | $1409 |
| Brand 5/7.5/10/12.5/15 mg | brand | $1409 |
| Brand 0.25/0.5/1/1.7/2.4 mg | brand | $1409 |
✓ Pros
- •Brand-name FDA-approved GLP-1 receptor agonists (Ozempic, Mounjaro, Wegovy) on a single platform — no compounded-product YMYL risk
- •LegitScript Approved (#44796030)
- •42-state US coverage with 8-state Phase 2 expansion roadmap published
- •Multi-product platform appeals to patients managing multiple conditions (GLP-1 + sexual health + hair loss + mental health) on one subscription
✗ Cons
- •Stacked-fee structure is expensive: $99 consultation + $99/mo program fee + $1,409/mo medication = ~$1,508/mo first month, ~$1,508/mo ongoing — well above typical compounded providers ($99-$199/mo all-in) and above LillyDirect Self Pay Journey Program ($449-$699/mo Zepbound vials)
- •Canadian incorporation (Rocky Health Inc., Mississauga, ON L4W 5M8) with US-state prescriber operationalization opaque — patients should verify their state's prescriber holds an active US license before enrolling
- •Listed pharmacy (Rocky Pharmacy #308582, Mississauga ON) is a Canadian community pharmacy — US-fulfillment supply chain not transparent on public-facing pages
- •Multi-product platform may indicate prescriber bandwidth is split across many conditions (less GLP-1-specific expertise vs single-product specialists)
- •Brand-only (no compounded option) limits cost-sensitive patient access
- •$1,409/mo Ozempic pricing is near-retail; insured patients should pursue PA through traditional pharmacy for better economics — uninsured patients should compare NovoCare ($349/mo Wegovy pen ongoing) or LillyDirect Self Pay ($449-$699/mo Zepbound vials)
Ready to start with myRocky?
Starting at $1409/month. See current pricing and start your free consultation.
Sources & methodology
Our myRocky review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
Alternatives to myRocky
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with myRocky?
Starting at $1409/month. See current pricing and start your free consultation.